Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Elacentra is indicated for:
Pharmacology
Elacestrant is an estrogen receptor antagonist, and it works by binding to estrogen receptor-alpha (ERα). In ER-positive (ER+) HER2-negative (HER2-) breast cancer cells, it inhibited the cell proliferation driven by 17β-estradiol. This happened at concentrations that also caused the ERα protein to break down through the proteasomal pathway. Elacestrant showed antitumor activity both in vitro and in vivo. That included ER+ HER2- breast cancer models resistant to fulvestrant and to cyclin-dependent kinase 4/6 inhibitors, and models carrying estrogen receptor 1 gene (ESR1) mutations.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Patient Selection
Elacestrant is for ER-positive, HER2-negative advanced or metastatic breast cancer, and patients should be selected for treatment based on the presence of ESR1 mutation(s) in a plasma specimen, using an FDA-approved test.
Recommended Dosage
The recommended dosage of Elacestrant is 345 mg taken orally with food once daily. Treatment continues until the disease progresses or unacceptable toxicity occurs. Take Elacestrant at about the same time each day, and take it with food to reduce nausea and vomiting.
Swallow the tablet(s) whole. Do not chew, crush or split them before swallowing. Do not take any Elacestrant tablets that are broken, cracked or look damaged.
If a dose is missed for more than 6 hours, or if vomiting occurs, skip that dose and take the next dose the following day at the usual scheduled time.
Side Effects
Elacestrant most often causes (in more than 10% of people) musculoskeletal pain, nausea, fatigue, vomiting, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush and dyspepsia. Some changes show up only in blood tests: increased cholesterol, increased AST, increased triglycerides, increased ALT, increased creatinine, decreased hemoglobin and decreased sodium.
Cautions & Contraindications
Warnings & Precautions
Dyslipidemia: Hypercholesterolemia and hypertriglyceridemia occurred in patients taking Elacestrant, at an incidence of 30% and 27%, respectively. For Grade 3 and 4 events, the incidence was 0.9% for hypercholesterolemia and 2.2% for hypertriglyceridemia. Embryo-Fetal Toxicity: Going by findings in animals and how the medicine works, it can cause fetal harm when given to a pregnant woman. In pregnant rats, it led to adverse developmental outcomes, including embryo-fetal mortality and structural abnormalities, at maternal exposures below the recommended dose based on area under the curve (AUC). Advise pregnant women and females of reproductive potential about the potential risk to a fetus. Females of reproductive potential should be advised to use effective contraception during treatment with Elacestrant and for 1 week after the last dose. Male patients with female partners of reproductive potential should likewise be advised to use effective contraception during treatment and for 1 week after the last dose.
Pregnancy & Breastfeeding
Animal findings and the way Elacestrant works both point to a risk of harm to the baby if a pregnant woman takes it. There are no human data on its use in pregnancy, so the actual risk isn't known.
Nothing is known about whether elacestrant passes into human milk, whether it affects milk production, or what it might do to a breastfed child. Because the breastfed child could have serious adverse reactions, women who are breastfeeding should be advised not to breastfeed during treatment with Elacestrant and for 1 week after the last dose.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Store Elacestrant below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Common questions about Elacentra 345 mg
What is Elacentra 345 mg Tablet?
Elacentra 345 mg Tablet is a medicine that contains Elacestrant. It is made by Beacon Pharmaceuticals PLC. It belongs to the Cytotoxic Chemotherapy group of medicines.
What is Elacentra used for?
Elacentra is used for: Cancer.
What are the side effects of Elacentra?
Elacestrant most often causes (in more than 10% of people) musculoskeletal pain, nausea, fatigue, vomiting, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush and dyspepsia. Some changes show up only in blood tests: increased cholesterol, increased AST, increased triglycerides, increased ALT, increased creatinine, decreased hemoglobin and decreased sodium.
Can I take Elacentra during pregnancy or while breastfeeding?
Animal findings and the way Elacestrant works both point to a risk of harm to the baby if a pregnant woman takes it. There are no human data on its use in pregnancy, so the actual risk isn't known. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Elacentra?
Store Elacestrant below 30°C, and keep it away from light and moisture. Keep it out of the reach of children.
Is there a cheaper medicine with the same ingredient?
Elacentra is already among the lowest-priced brands of Elacestrant at this strength.
Do I need a prescription for Elacentra?
Elacentra is a prescription (Rx) medicine. Take it as your doctor advises.